Revenue
No reported data
Tevogen Inc. (TVGN)
Price—Loading quote
Net income
2022
2023
2024
2025
Free cash flow
2023
2025
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Research & development | $11.1M | $31.0M | $4.4M | — |
| Operating expenses | $26.1M | $53.6M | $8.8M | — |
| Operating income | −$26.1M | −$53.6M | −$8.8M | — |
| Net income | −$26.3M | −$13.7M | −$60.5M | $4.4M |
| Basic EPSper diluted share | -$8.08 | -$3.50 | -$2.44 | — |
| Diluted EPSper diluted share | -$8.08 | -$3.50 | -$2.44 | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 13, 2026Form 4 | Flomenberg NealSee Remarks | SellCommon Stock | 501 | $6.40 | $3.2K | 76.9K |
| Mar 11, 2026Form 4 | Flomenberg NealSee Remarks | SellCommon Stock | 452 | $7.26 | $3.3K | 77.4K |
| Mar 10, 2026Form 4 | Flomenberg NealSee Remarks | SellCommon Stock | 19 | $7.75 | $147.25 | 77.9K |
| Jun 9, 2025Form 4 | Saadi Ryan H.Chief Executive Officer | SellCommon Stock | 1.44M | $1.23 | $1.77M | 116.81M |
| Mar 12, 2025Form 4 | Flomenberg NealSee Remarks | SellCommon Stock | 233.0K | $1.09 | $253.9K | 3.60M |